Bionano Genomics announces full commercial release of Stratys system

Bionano Genomics announced the full commercial release of the Stratys system, the Company’s system for high throughput optical genome mapping. As part of an early access program, the following 10 sites have adopted a total of 11 Stratys systems: BC Cancer – Vancouver; Hamilton Health Sciences; Henry Ford Health System; National Guard Hospital; NHS Northwest Genomic Laboratory Hub; Radboud University Medical Center; UZ Brussel and Cliniques universitaires Saint-Luc; Vancouver General Hospital; Additional sites that Bionano is not able to name publicly include a United States-based high-volume centralized reference laboratory and a United States-based leading academic medical center specializing in cancer treatment. Erik Holmlin, PhD, president and chief executive officer of Bionano, commented, “We believe today marks an important day for anyone seeking to implement OGM at scale, with the announcement of commercial availability of Stratys, the first high throughput OGM system, which can shorten time-to-results, reduce hands-on-time and help reveal new actionable insights across research applications including heme malignancies, constitutional genetic disorders and cell and gene therapy. We launched an early access program for our Stratys system in 2023 to great enthusiasm, with orders exceeding our initial offering of 10 systems, many from new OGM adopters. We are excited to see these early access sites partner with us as we extend Stratys adoption across the world.”